Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2025)

Barinthus Biotherapeutics' Revenue history spans 6 years, with the latest figure at $1000.0 for Q2 2025.

  • For Q2 2025, Revenue changed N/A year-over-year to $1000.0; the TTM value through Dec 2025 reached $317000.0, down 97.88%, while the annual FY2024 figure was $15.0 million, 1766.46% up from the prior year.
  • Revenue reached $1000.0 in Q2 2025 per BRNS's latest filing, down from $316000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $17.1 million in Q2 2022 to a low of -$1000.0 in Q4 2021.
  • Average Revenue over 5 years is $4.7 million, with a median of $334000.0 recorded in 2023.
  • Peak YoY movement for Revenue: plummeted 100.28% in 2021, then surged 645800.0% in 2022.
  • A 5-year view of Revenue shows it stood at -$1000.0 in 2021, then soared by 645800.0% to $6.5 million in 2022, then plummeted by 94.83% to $334000.0 in 2023, then surged by 4381.74% to $15.0 million in 2024, then plummeted by 99.99% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Revenue are $1000.0 (Q2 2025), $316000.0 (Q1 2025), and $15.0 million (Q3 2024).